Previously submitted to: JMIR Mental Health (no longer under consideration since Feb 15, 2024)
Date Submitted: Feb 15, 2024
Open Peer Review Period: Feb 15, 2024 - Feb 15, 2024
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Assessment of beliefs and attitudes towards benzodiazepines using machine learning based on social media posts: An observational Study.
ABSTRACT
Background:
Benzodiazepines are frequently prescribed drugs. However, its prolonged use generates tolerance, dependence, and other adverse effects. Despite this, its long-term use is common, which is a public health problem.
Objective:
The objective of this study is to delve into the beliefs and opinions that the population has about benzodiazepines, since it can shed light on their pattern of use.
Methods:
We collected public tweets published in English between January 1, 2019 and October 31, 2020 that contained mentions to benzodiazepines. The content of each tweet and the characteristics of the users were analyzed using a mixed methodology that included manual analysis and semi-supervised machine learning.
Results:
More than half of Twitter users mentioned the good efficacy of benzodiazepines, speaking minimally about their side effects. The most active users in these conversations are the patients themselves and their families, being the presence of health professionals and institutions almost non-existent. On the other hand, the most named drugs coincide with those most prescribed by professionals.
Conclusions:
Social media platforms provide information about the experiences and opinions that users have about a drug, and interestingly, their sentiment about benzodiazepines is positive, considering them effective drugs, without referring to side effects. This analysis indicates that there is a need to educate physicians, patients, and relatives of the potential risks associated with the use of benzodiazepines, as well as to promote clinical guidelines that help to manage these medications properly.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.